510(k) Report

510(k) · Cleared

Recalled · Class II · 2020

Wako Direct Bilirubin V, Models 996-23591, 412-22901, 992-23691, 998-23791

K053132510(k) TraditionalCleared Dec 30, 200552-day reviewClass II21 CFR 862.1110Recalls 2

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Wako Chemicals USA, Inc. · JFM Enzymatic Method, Bilirubin

Cleared on Dec 30, 2005 as substantially equivalent to K970986 (Wako Chemicals USA, Inc., 1997) after a 52-day review. Its family tree reaches back 2 generations to 1991. 2 later devices descend from it. It has been recalled 2 times.

Decided
Dec 30, 2005
Review
52 days
Class
Class II
Product code
JFM
Recalls
2
Predicates
1

Its longest line of descent runs back 2 generations to K912024 (1991). 2 later devices descend from it, 2 citing it directly.

Descendants, by year cleared 2023: 1 descendant cleared2016: 1 descendant clearedK912024 · Automated Biochemical Analyzer (WAK0-20R & 30R) · Wako Chemicals USA, Inc. · 1991K970986 · Wako Direct Bilirubin V · Wako Chemicals USA, Inc. · 19971990200020102020
Descendants, by generation 1 generation forward: 2 descendants K970986 · Wako Direct Bilirubin V · Wako Chemicals USA, Inc. · 1997K912024 · Automated Biochemical Analyzer (WAK0-20R & 30R) · Wako Chemicals USA, Inc. · 19910
  1. Root · 2 generations backK912024 Automated Biochemical Analyzer (WAK0-20R & 30R)Wako Chemicals USA, Inc. · 1991
  2. 1 generation backK970986 Wako Direct Bilirubin VWako Chemicals USA, Inc. · 1997
  3. This deviceK053132 Wako Direct Bilirubin V, Models 996-23591, 412-22901, 992-23691…Wako Chemicals USA, Inc. · 2005
  4. Descendant · cites it directly · 0 of its ownK223078 Atellica® CH Diazo Direct Bilirubin (D_DBil)Siemens Healthcare Diagnostics, Inc. · 2023
  5. Descendant · cites it directly · 0 of its ownK152343 Direct BilirubinRandox Laboratories Limited · 2016

Most influential descendants

Showing 2 of 2 · See all
  • K223078Atellica® CH Diazo Direct Bilirubin (D_DBil)Siemens Healthcare Diagnostics, Inc. · 2023 · cites it directly0descendants
  • K152343Direct BilirubinRandox Laboratories Limited · 2016 · cites it directly0descendants
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−2K912024Automated Biochemical Analyzer (WAK0-20R & 30R)Wako Chemicals USA, Inc.1991—
−1K970986Wako Direct Bilirubin VWako Chemicals USA, Inc.1997—
0 (this device)K053132Wako Direct Bilirubin V, Models 996-23591, 412-22901, 992-23691, 998-23791Wako Chemicals USA, Inc.2005—
+1K223078Atellica® CH Diazo Direct Bilirubin (D_DBil)Siemens Healthcare Diagnostics, Inc.2023—
+1K152343Direct BilirubinRandox Laboratories Limited2016—

Descendants by year cleared

Year clearedDevicesWith a Class I recall
201610
202310
FIG. 1 — Lineage of K053132, 1991–2023Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in JFM? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

  • Candidate predicates for a device like this, rankedin the report
  • Recall history across each candidate’s familyin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K970986Wako Direct Bilirubin V
Summary page 1
…ation. The safety and effectiveness of the Wako Direct Bilirubin V assay is demonstrated by its substantial equivalency to our previous Direct Bilirubin assay (510(K) # 970986). The previously marketed device (51 Ok# 970986) was marketed for serum samples and this submission adds the use of plasma as a s…
Wako Chemicals USA, Inc.1997—

Also cleared against K970986: 1 other device →

What descends from it? (2)

2 later devices cite it directly; ranked here by how many devices descend from each in turn.

NumberDeviceApplicantDecidedDescendants
K223078Atellica® CH Diazo Direct Bilirubin (D_DBil)Siemens Healthcare Diagnostics, Inc.20230
K152343Direct BilirubinRandox Laboratories Limited20160

Has anything in its family been recalled? (0 Class I)

Recalls of this device

DateClassRecallRoot causeReason
Feb 13, 2020Class IIZ-1536-2020Under Investigation by firmBilirubin assays may exhibit a positive bias with patients on eltrombopag therapy
Feb 13, 2020Class IIZ-1538-2020Under Investigation by firmBilirubin assays may exhibit a positive bias with patients on eltrombopag therapy

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 14 years and passes through 1 company; a new generation was cleared every 8.6 years on median.
  • None of the 2 ancestors has a recall.
  • Of its descendants, K223078 (Siemens Healthcare Diagnostics, Inc., 2023) has gone furthest, with 0 descendants of its own.
  • 1 other device also cites its predicate K970986.

How does its category compare?

All JFM devices

JFM Enzymatic Method, Bilirubin: FDA decisions, review times, recalls and adverse event reports over 20 years.

FDA decisions per year · JFM

1in 2017

2007: 12016: 22017: 1
2007high 2 (2016) · low 0 (2008)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · JFM

Too few JFM 510(k)s in any year since 2007 to give a median.

Recalls per year · JFM

1in 2023

2023: 1
2007high 1 (2023) · low 0 (2007)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · JFM

1in 2025

2007: 82008: 22010: 72011: 62012: 12015: 22021: 12023: 12024: 12025: 1
2007high 8 (2007) · low 0 (2009)2025

MAUDE reports naming product code JFM, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20071—08
20080—02
20090—00
20100—07
20110—06
20120—01
20130—00
20140—00
20150—02
20162—00
20171—00
20180—00
20190—00
20200—00
20210—01
20220—00
20230—11
20240—01
20250—01
20260—0—

What is it indicated for?

Determination of serum and plasma bilirubin is useful in the screening of liver function disorders or in the diagnosis of jaundice.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K053132: Wako Direct Bilirubin V, Models 996-23591, 412-22901, 992-23691, 998-23791.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K053132

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026